Speciality: Oncology
Description:
Dr. Srinivas K G presents a compelling retrospective analysis titled "ESMO Breast Cancer 2022: P REALITY X" in this insightful video. The discussion delves into the real-world efficacy and clinical outcomes of a specific breast cancer treatment regimen, as examined during the ESMO Breast Cancer 2022 conference. Dr. Srinivas meticulously reviews the data, highlighting key findings, patient responses, and the implications for future therapeutic strategies. His expertise provides valuable perspectives for oncologists and researchers seeking to optimize breast cancer management.
The video explores the retrospective study design, patient demographics, and survival outcomes analyzed in the P REALITY X trial. Dr. Srinivas emphasizes the importance of real-world evidence in complementing randomized clinical trials, offering a more comprehensive understanding of treatment effectiveness in diverse populations. He also addresses potential limitations and biases inherent in retrospective analyses, ensuring a balanced interpretation of the results. This session is a must-watch for medical professionals aiming to stay updated on the latest advancements in breast cancer research.
Dr. Srinivas K G’s detailed breakdown of the P REALITY X study serves as an invaluable resource for the oncology community. By bridging the gap between clinical trials and real-world practice, his analysis fosters a deeper appreciation for evidence-based decision-making. Stay tuned for more expert discussions and cutting-edge insights in upcoming videos. Your journey towards mastering breast cancer therapeutics continues here!
See More Webinars @ Hidoc Webinars
1.
Inner Thoughts of Leonard Bernstein, the "Maestro".
2.
Mobile prostate cancer screening clinic can ID the disease in disadvantaged men
3.
No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC
4.
Parents, teachers at Missouri school want answers after string of cancer diagnoses
5.
A promising medication could slow brain tumors in children.
1.
Future-Ready Cancer Screening: What Every Clinician Should Know in 2025
2.
Cancer Evolution and Therapeutic Resistance: Mechanisms, Clinical Insights, and Emerging Strategies
3.
Targeting Cancer Stem Cells in Solid Tumors: Mechanisms, Clinical Implications, and Therapeutic Advances
4.
Partial Gland Ablation in Prostate Cancer: Oncologic Outcomes in Intermediate-Risk Cases
5.
Generative AI for Adaptive Oncology Trial Design
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
5.
Current Scenario of Cancer- The Incidence of Cancer in Men
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation